BridgeBio Pharma: Attruby Becomes a Blockbuster – Main Competitor Fails in Phase 3 Trial

Attruby experienced almost 400% growth in the US as a treatment for the rare heart disease ATTR-CM. The competitor Wainua failed in the Phase 3 trial. BBP-418, Encaleret, and Infigratinib could potentially become first-line therapies for rare diseases with submitted and planned regulatory applications. Attruby is expected to become a blockbuster by 2026. With nearly $2 billion in financial reserves, the launch of the pipeline is expected to be accelerated.   BridgeBio Pharma (BBIO) specializes in precision medicine focusing on treatment...